Trial Profile
A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 22 Aug 2016 New trial record
- 10 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.